IP Library Granted Patent US 7,101,914
Granted Patent B2
US 7,101,914 · App. 10/700,000 · Granted Sep 5, 2006

Isomer enriched conjugated linoleic acid compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,101,914
App. No.
10/700,000
Granted
Sep 5, 2006
Kind
B2
Abstract

Compositions and methods of using conjugated linoleic acid preparations enriched for the t10,c12 and c9,t11 isomers are disclosed. It is found that preparations of conjugated linoleic acid containing a ratio of t10,c12 to c9,t11 of about greater than 1.2:1 are desirable for a wide variety of nutritional, therapeutic and pharmacologic uses.

Claims (14)

1. A method of elevating white blood cell count in a mammal comprising:

a) providing a CLA composition comprising t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid in a ratio of about 1.2:1 to 3:1 and a mammal; and

b) administering said CLA composition to said mammal under conditions such that CD4 and CD8 counts are elevated.

2. The method of claim 1 , wherein said CLA composition is administered orally.

3. The method of claim 1 , wherein said CLA composition comprises free fatty acids of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

4. The method of claim 1 , wherein said CLA composition comprises esters of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

5. The method of claim 1 , wherein said CLA composition comprises acylglycerides of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

6. A method of attenuating allergic rections in a mammal comprising:

a) providing a CLA composition comprising t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid in a ratio of about 1.2:1 to 3:1 and a mammal; and

b) administering said CLA composition to said mammal under conditions such that said allergic reactions are attenuated.

7. The method of claim 6 , wherein said CLA composition is administered orally.

8. The method of claim 6 , wherein said CLA composition comprises free fatty acids of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

9. The method of claim 6 wherein said CLA composition comprises esters of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

10. The method of claim 6 , wherein said CLA composition comprises acylglycerides of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

Assignments (3)
CHANGE OF NAME Recorded Sep 7, 2007
From: NATURAL ASA
To: AKER BIOMARINE ASA
Reel/Frame 019805/0274 →
CHANGE OF NAME Recorded Sep 7, 2007
From: NATURAL ASA
To: AKER BIOMARINE ASA
Reel/Frame 019805/0418 →
RE-RECORD TO CORRECT THE ADDRESS OF THE ASSIGNEE. Recorded Feb 3, 2006
From: NATURAL CORPORATION
To: NATURAL ASA
Reel/Frame 017240/0646 →